Literature DB >> 28283344

"Gotta Catch 'em All", or Do We? Pokemet Approach to Metastatic Prostate Cancer.

Declan G Murphy1, Christopher J Sweeney2, Bertrand Tombal3.   

Abstract

Metastasis-directed therapy is of interest for the management of oligometastatic prostate cancer. Improved imaging may help with patient selection, but the approach to metastatic prostate cancer of "catching 'em all", or "Pokemet", must be considered experimental.
Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Year:  2017        PMID： 28283344     DOI： 10.1016/j.eururo.2017.02.036

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


  18 in total

1.  Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time.

Authors:  Bert Dhondt; Elise De Bleser; Tom Claeys; Sarah Buelens; Nicolaas Lumen; Jo Vandesompele; Anneleen Beckers; Valerie Fonteyne; Kim Van der Eecken; Aurélie De Bruycker; Jérôme Paul; Pierre Gramme; Piet Ost
Journal:  World J Urol       Date:  2018-12-21       Impact factor: 4.226

Review 2.  PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics.

Authors:  R S Eapen; T C Nzenza; D G Murphy; M S Hofman; M Cooperberg; N Lawrentschuk
Journal:  World J Urol       Date:  2018-10-29       Impact factor: 4.226

3.  PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA-targeted PET Imaging Studies.

Authors:  Steven P Rowe; Kenneth J Pienta; Martin G Pomper; Michael A Gorin
Journal:  Eur Urol       Date:  2017-11-11       Impact factor: 20.096

4.  Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories.

Authors:  Yafu Yin; Rudolf A Werner; Takahiro Higuchi; Constantin Lapa; Kenneth J Pienta; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  J Nucl Med       Date:  2018-09-06       Impact factor: 10.057

5.  Pattern of metastatic deposit in recurrent prostate cancer: a whole-body MRI-based assessment of lesion distribution and effect of primary treatment.

Authors:  Vassiliki Pasoglou; Nicolas Michoux; Julien Van Damme; Sandy Van Nieuwenhove; Marin Halut; Perrine Triqueneaux; Bertrand Tombal; Frédéric E Lecouvet
Journal:  World J Urol       Date:  2019-03-02       Impact factor: 4.226

Review 6.  [Imaging of oligometastatic disease in selected urologic cancers].

Authors:  S A Koerber; C A Fink; K Dendl; D Schmitt; G Niegisch; E Mamlins; F L Giesel
Journal:  Urologe A       Date:  2021-11-30       Impact factor: 0.639

Review 7.  [The role of PSMA PET-CT in patients with metastatic prostate cancer].

Authors:  J von Hardenberg; K-A Büsing; P Nuhn; M Ritter
Journal:  Urologe A       Date:  2017-11       Impact factor: 0.639

Review 8.  [The role of PSMA PET-CT in patients with metastatic prostate cancer].

Authors:  J von Hardenberg; K-A Büsing; P Nuhn; M Ritter
Journal:  Radiologe       Date:  2018-03       Impact factor: 0.635

Review 9.  Chemotherapy for oligometastatic prostate cancer.

Authors:  Tanya B Dorff; Christopher J Sweeney
Journal:  Curr Opin Urol       Date:  2017-11       Impact factor: 2.808

10.  Outcome after PSMA PET/CT based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a bi-institutional retrospective analysis.

Authors:  Nina-Sophie Schmidt-Hegemann; Christian Stief; Tak-Hyun Kim; Chukwuka Eze; Simon Kirste; Iosif Strouthos; Minglun Li; Wolfgang Schultze-Seemann; Harun Ilhan; Wolfgang Peter Fendler; Peter Bartenstein; Anca-Ligia Grosu; Ute Ganswindt; Claus Belka; Philipp T Meyer; Constantinos Zamboglou
Journal:  J Nucl Med       Date:  2018-07-12       Impact factor: 10.057
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.